Radius Health to Present Promising Single-Agent Data for Investigational Oral Drug RAD1901 at 2015 American Association for Cancer Research — National Cancer Institute — European Organisation for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference

On November 2, 2015 Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patiereported that it will present new data on investigational oral drug RAD1901 at the AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) to be held at the Hynes Convention Center in Boston, Massachusetts USA on November 7 and 8, 2015 (Press release, Radius, NOV 2, 2015, View Source [SID:1234507875]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will present one oral and one poster presentation showing promising activity for its investigational oral drug RAD1901, a selective estrogen receptor degrader (SERD), in preclinical models of advanced estrogen-receptor-positive (ER+) breast cancer. Data showed that the investigational drug RAD1901 has potent anti-tumor activity in multiple patient-derived xenograft models including those that were insensitive to other hormonal agents as well as models that harbor ESR1 mutations.

"These encouraging data solidify the potential promise of investigational drug RAD1901 and we look forward to continuing its development in breast cancer," said Dinesh Purandare, SVP and Head of Global Oncology, Radius Health. "We believe there is significant unmet need for innovative therapies for metastatic breast cancer, particularly in patients with tumors that are resistant to current hormonal agents, and we are committed to bringing this medicine forward to the patients who need it most."

According to the World Health Organization, breast cancer is the second most common cancer in the world and the most prevalent cancer in women, accounting for sixteen percent of all female cancers. Approximately seventy percent of breast cancer patients are ER+ with tumors that depend on estrogen signaling for growth and survival. SERDs, such as the investigational drug RAD1901, are an emerging class of endocrine therapies that directly induce ER degradation, potentially enabling them to treat ER-dependent tumors without allowing treatment resistance to develop.

Poster and Oral Presentation Information:

Title: RAD1901, an orally available selective estrogen receptor downregulator, has potent anti-tumor activity in in vitro and in vivo models of ER+ breast cancer
Abstract Number: PR10
Session/Poster: Oral Presentation
Date and Time: Saturday, Nov 7, 2015, 5:54 PM – 6:06 PM
Location: Boston Hynes Convention Center, Ballroom C

Title: RAD1901, an orally available selective estrogen receptor downregulator, has potent anti-tumor activity in in vitro and in vivo models of ER+ breast cancer
Abstract Number: C100
Session/Poster: Poster Board Number C100
Date and Time: Sunday, Nov 8, 2015, 12:30 PM – 3:30 PM
Location: Boston Hynes Convention Center, Session C, Hall C-D